Corcept Therapeutics (CORT) Gross Profit (2012 - 2026)

Corcept Therapeutics has reported Gross Profit for 15 years, with the latest figure at $252.1 million in Q2 2026.

• Quarterly Gross Profit rose 31.98% year-over-year to $252.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $816.7 million (up 15.94% YoY) and the FY2025 annual result came in at $748.4 million, up 12.69% from the prior year.
• Gross Profit improved to $252.1 million in Q2 2026 per CORT's latest filing, from $162.0 million in the prior quarter.
• Over five years, Gross Profit peaked at $252.1 million in Q2 2026 and troughed at $92.4 million in Q1 2022.
• A 5-year average of $149.9 million and a median of $149.5 million in 2024 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2024: Gross Profit climbed 4.21% in 2022, then jumped 47.33% in 2024.
• Over 5 years, Gross Profit stood at $101.6 million in 2022, then jumped by 31.46% to $133.5 million in 2023, then surged by 34.0% to $178.9 million in 2024, then increased by 11.54% to $199.6 million in 2025, then grew by 26.31% to $252.1 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $252.1 million, $162.0 million, and $199.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.